Literature DB >> 23494466

Generic substitution, financial interests, and imperfect agency.

Maurus Rischatsch1, Maria Trottmann, Peter Zweifel.   

Abstract

Policy makers around the world seek to encourage generic substitution. In this paper, the importance of prescribing physicians' imperfect agency is tested using the fact that some Swiss jurisdictions allow physicians to dispense drugs on their own account (physician dispensing, PD) while others disallow it. We estimate a model of physician drug choice with the help of drug claim data, finding a significant positive association between PD and the use of generics. While this points to imperfect agency, generics are prescribed more often to patients with high copayments or low incomes.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23494466     DOI: 10.1007/s10754-013-9126-5

Source DB:  PubMed          Journal:  Int J Health Care Finance Econ        ISSN: 1389-6563


  15 in total

1.  Optimal payment systems for health services.

Authors:  R P Ellis; T G McGuire
Journal:  J Health Econ       Date:  1990       Impact factor: 3.883

2.  Impact of a generic substitution reform on patients' and society's expenditure for pharmaceuticals.

Authors:  Karolina Andersson; Gina Bergström; Max G Petzold; Anders Carlsten
Journal:  Health Policy       Date:  2006-09-01       Impact factor: 2.980

3.  Financial incentives and physicians' prescription decisions on the choice between brand-name and generic drugs: evidence from Taiwan.

Authors:  Ya-Ming Liu; Yea-Huei Kao Yang; Chee-Ruey Hsieh
Journal:  J Health Econ       Date:  2008-11-05       Impact factor: 3.883

4.  An economic analysis of payment for health care services: the United States and Switzerland compared.

Authors:  Peter Zweifel; Ming Tai-Seale
Journal:  Int J Health Care Finance Econ       Date:  2009-04-09

5.  Pharmaceutical reform in South Korea and the lessons it provides.

Authors:  Hak-Ju Kim; Jennifer Prah Ruger
Journal:  Health Aff (Millwood)       Date:  2008-05-28       Impact factor: 6.301

6.  Experts' agency problems: evidence from the prescription drug market in Japan.

Authors:  Toshiaki Iizuka
Journal:  Rand J Econ       Date:  2007

7.  Moral hazard in physician prescription behavior.

Authors:  D Lundin
Journal:  J Health Econ       Date:  2000-09       Impact factor: 3.883

Review 8.  Pharmacists and prescribing rights: review of international developments.

Authors:  Lynne Emmerton; Jennifer Marriott; Tracey Bessell; Lisa Nissen; Laura Dean
Journal:  J Pharm Pharm Sci       Date:  2005-08-04       Impact factor: 2.327

9.  Technology in ambulatory medical care: cost increasing or cost saving?

Authors:  P Zweifel
Journal:  Soc Sci Med       Date:  1985       Impact factor: 4.634

10.  Provider behavior under prospective reimbursement. Cost sharing and supply.

Authors:  R P Ellis; T G McGuire
Journal:  J Health Econ       Date:  1986-06       Impact factor: 3.883

View more
  6 in total

1.  What do physicians dislike about managed care? Evidence from a choice experiment.

Authors:  Maurus Rischatsch; Peter Zweifel
Journal:  Eur J Health Econ       Date:  2012-06-21

2.  The diffusion of generics after patent expiry in Germany.

Authors:  Katharina Elisabeth Fischer; Tom Stargardt
Journal:  Eur J Health Econ       Date:  2015-11-16

3.  Lead me not into temptation: drug price regulation and dispensing physicians in Switzerland.

Authors:  Maurus Rischatsch
Journal:  Eur J Health Econ       Date:  2013-07-18

4.  Medical ethics: enhanced or undermined by modes of payment?

Authors:  Peter Zweifel; Katharina Janus
Journal:  Eur J Health Econ       Date:  2016-04-12

5.  Prescription of potentially inappropriate medication in older persons in Switzerland: does the dispensing channel make a difference?

Authors:  Eva Blozik; Roland Rapold; Oliver Reich
Journal:  Risk Manag Healthc Policy       Date:  2015-04-24

6.  Physician drug dispensing in Switzerland: association on health care expenditures and utilization.

Authors:  Maria Trottmann; Mathias Frueh; Harry Telser; Oliver Reich
Journal:  BMC Health Serv Res       Date:  2016-07-08       Impact factor: 2.655

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.